Research and experimental development on natural sciences and engineering
ALGIPHARMA AS
Revenue 2024
NOK 6,000
Operating profit
NOK −6.9m
Equity
NOK 176.1m
Incorporated
1992
Employees
6
Share capital
NOK 2.8m
Key figures · 2024
Current ratio
0.35
Equity ratio
85.0%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -119526.4% | |
| Net margin (%%) | -156195.6% | |
| Return on assets (%%) | -3.3% | |
| Likviditet | ||
| Current ratio | 0.35 | |
| Working capital | −10.6m | |
| Soliditet | ||
| Equity ratio (%%) | 85.0% | |
| Debt-to-equity ratio | 0.18 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.